GSK’s Vi­iV stops de­vel­op­ment of Phase 2 HIV an­tivi­ral

GSK’s Vi­iV Health­care has sus­pend­ed de­vel­op­ment of a Phase 2-stage HIV an­tivi­ral named VH3739937, a GSK spokesper­son con­firmed to End­points News on Tues­day.

The halt …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER